Edition:
India

People: Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

241.01USD
11:29pm IST
Change (% chg)

$0.69 (+0.29%)
Prev Close
$240.32
Open
$239.51
Day's High
$241.13
Day's Low
$237.81
Volume
448,488
Avg. Vol
1,185,211
52-wk High
$264.97
52-wk Low
$177.05

Druker, Brian 

DR. Brian J. Druker M.D. serves as Independent Director of the Company. Dr. Druker joined Oregon Health & Science University, or OHSU, in 1993 and is currently a physician-scientist and professor of medicine. Dr. Druker has served as the director of the OHSU Knight Cancer Institute since 2007, associate dean for oncology of the OHSU School of Medicine since 2010, and the JELD-WEN chair of leukemia research at OHSU since 2001. He was an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, from 2002 to 2019. Dr. Druker has served on the scientific advisory board of Aptose Biosciences Inc., a biotechnology company, since 2013. Dr. Druker was on the scientific advisory board of Grail, Inc., a biotechnology company, from 2016 to 2019. In 2011, he founded Blueprint Medicines Corporation, a biopharmaceutical company, and remains as a scientific advisor to this company. In 2006, he founded MolecularMD, a privately-held molecular diagnostics company that was acquired by ICON plc in 2019. Dr. Druker has received numerous awards, including the Lasker-DeBakey Clinical Research Award in 2009, the Japan Prize in Healthcare and Medical Technology in 2012, the Albany Medical Center Prize in 2013, and the Sjöberg Prize in 2019, for influential work in the development of STI571 (Gleevec®) for the treatment of chronic myeloid leukemia. He was elected to the National Academy of Sciences in 2012 as well as the National Academy of Medicine in 2007. Dr. Druker received both an undergraduate degree and his doctorate from the University of California, San Diego.

Basic Compensation

Total Annual Compensation, USD 125,000
Restricted Stock Award, USD 199,828
Long-Term Incentive Plans, USD --
All Other, USD 20,327
Fiscal Year Total, USD 345,155

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --